Glucagon-like peptide-1 analogues (GLP-1As) are now well-established and widely used agents for the treatment of obesity, and they have demonstrated superior efficacy compared to insulin and metformin in the management of T2DM. This evidence concerns the gene GCG and obesity disorder.